新型抗尿路上皮癌药物atezolizumab

Atezolizumab:a new drug for urothelial carcinoma

atezolizumab是由基因泰克公司开发的一种结合于程序性死亡分子配体1(PD-L1)的单克隆抗体,用于局部晚期或转移尿路上皮癌患者。该药于2016年5月18日通过美国食品和药物管理局批准上市。本文对其药理作用、药动学、临床研究、安全性等作一概述。

Atezolizumab is a monoclonal antibody that binds to death ligand 1 （PD-L1 ）, developed by Genentech. It was approved for patients with locally advanced or metastatic urothelial carcinoma by the U.S. Food and Drug Administration on May 18, 2016. The pharmacology, pharmacokinetics, clinical research, and safety of atezolizumab were reviewed in this paper.